TransThera Sciences (Nanjing) Inc.
public_traded
TransThera Sciences (Nanjing) Inc. is publicly traded on HKSE under ticker 2617.HK.
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor for the treatment of drug-resistant, relapsed, or refractory cancers. It also develops a pipeline of clinical stage product candidates and a preclinical stage product candidate. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.